US2023120597A1PendingUtilityA1

Co-agonists at glp-1 and gip receptors suitable for oral delivery

76
Assignee: NOVO NORDISK ASPriority: Jul 22, 2020Filed: Nov 4, 2022Published: Apr 20, 2023
Est. expiryJul 22, 2040(~14 yrs left)· nominal 20-yr term from priority
Inventors:Patrick James KnerrBrian FinanRichard D. Dimarchi
A61K 38/26C07K 14/605A61K 47/542A61K 47/64A61P 3/10A61P 3/04A61P 1/16A61K 38/00C07K 14/001
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.

Claims

exact text as granted — not AI-modified
1 . A compound comprising a peptide and a substituent, wherein the compound is 
       
         
           
           
               
               
           
         
         wherein the amino acid sequence of the peptide is SEQ ID NO:25;
 or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2023120597A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.